Retireful LLC Takes Position in BioNTech SE (NASDAQ:BNTX)

Retireful LLC purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,278 shares of the company’s stock, valued at approximately $260,000.

Other hedge funds also recently modified their holdings of the company. Planning Capital Management Corp increased its position in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. grew its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC increased its holdings in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in BioNTech in the 3rd quarter valued at about $210,000. Finally, Probity Advisors Inc. purchased a new stake in BioNTech during the third quarter valued at about $216,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 0.8 %

BNTX stock opened at $112.76 on Friday. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a market cap of $27.03 billion, a price-to-earnings ratio of -53.69 and a beta of 0.18. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $114.56 and its 200 day moving average is $104.12.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Sell-side analysts predict that BioNTech SE will post -3.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BNTX shares. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. JPMorgan Chase & Co. cut their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. Berenberg Bank assumed coverage on BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target for the company. Finally, Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.